In A Blow To AbbVie Inc (ABBV) Humira, Market For Biosimilars Opened Wide
Two patents that AbbVie Inc (NYSE:ABBV) held on Humira, a treatment for arthritis, have been invalidated by an English court.
Posts Tagged ‘Is ABBV A Good Stock To Buy Right Now?’
AbbVie Inc (ABBV) In Share Buyback Plan For The Third Year In A Row
The AbbVie Inc (NYSE:ABBV) board of directors has given the authorization required to increase $5 billion to the company’s existing share buyback program.
UK National Institute For Health And Care Excellence Rejects Leukemia Drug From AbbVie Inc (ABBV)
The National Institute for Health and Care Excellence has refused to authorize AbbVie Inc (NYSE:ABBV)'s Venclyxto on NHS.
Here’s What’s Important About The Latest AbbVie Inc (ABBV) Approval
AbbVie Inc (NYSE:ABBV) just announced that it has picked up approval for one of its lead development candidates, but the company has failed to really move on the announcement.
Emergent Technologies’ Pure MHC Explores A New Collaboration With AbbVie Inc (ABBV)
AbbVie Inc (NYSE:ABBV) has sought a joint venture with its target discovery portfolio company, Emergent Technologies Inc, Pure MHC.
Mylan NV (MYL), AbbVie Inc (ABBV) Sanofi SA (ADR) (SNY) In Spotlight Over Price Hikes
A Vermont drug price transparency bill threatens to make it hard for drug makers to increase drug prices without explanations.
AbbVie Inc (ABBV) Awaits NDA Approval For Hepatitis C Treatment
A New Drug Application (NDA) by AbbVie Inc (NYSE:ABBV) that will be used for the treatment of Hepatitis C is at the mercy the U.S. Food and Drug Administration.
Gilead Sciences, Inc. (GILD) Takes Lead Against AbbVie Inc (ABBV) On Crohn’s Disease Treatment
Gilead Sciences, Inc. (NASDAQ:GILD) might as well have quashed rumors making waves claiming it is planning to acquire Belgium-based Galapagos NV (ADR) (NASDAQ:GLPG).
December 2016 Stock Considerations
The final ‘stock considerations’ post of 2016 is finally at hand.
AbbVie Inc (ABBV) Wins Patent Battle Against Coherus Biosciences Inc (CHRS)
The US Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB) has decided not to embark on the review of the 166 formulation patent of AbbVie Inc (NYSE:ABBV) ...
AbbVie Inc (ABBV) Stock: Skyrocketing On IP Chatter | Coherus Biosciences Inc (CHRS) Stock Tanking
AbbVie Inc (NYSE:ABBV) and Coherus Biosciences Inc (NASDAQ:CHRS) were both off to a relatively normal start in the market today.
November 2016 Stock Considerations
As we near the home stretch of 2016 it seems like Mr. Market wants to give us some better buying opportunities compared to the recent months that have passed.
Four Dividend Champions On Sale
I usually look at dividend growth stocks and their dividend increases every week, as part of my portfolio monitoring process.
AbbVie Inc (ABBV) Expected To Launch Zinbryta In The US This Month
AbbVie Inc (NYSE:ABBV) and Biogen Inc (NASDAQ:BIIB) drug Zinbryta was approved by the Food and Drug Administration (FDA) as a therapy for adults suffering from relapsing forms...
Finding Reliable 3%+ Dividends in Today’s Market: AbbVie Inc (ABBV)
The financial markets today are filled with sand traps and water hazards; lower for longer crude oil prices, negative interest rate policies (NIRP), slow economic growth, the ...
AbbVie Inc (ABBV): A Cheap Dividend Aristocrat Yielding Over 4%
AbbVie Inc (NYSE:ABBV) is one of the more controversial dividend aristocrats for several reasons.
Dividend Aristocrats Part 47: AbbVie Inc (ABBV)
When it comes to the hedge fund sentiment, AbbVie is a rather popular stocks among the funds tracked by Insider Monkey.
